SCHEMBL2948700

SCHEMBL2948700

CCc1nc2cc(-c3ccc(C(=O)O)cc3)ccc2s1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.52
RAB9A P51151 5/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
GAA P10253 2/20 0.50
MAPK1 P28482 1/20 0.50
HDAC6 Q9UBN7 6/20 0.49
BCL2 P10415 1/20 0.48
RXRA P19793 2/20 0.48
RXRB P28702 2/20 0.48
LIPG Q9Y5X9 2/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
POLB P06746 1/20 0.43
MAPT P10636 1/20 0.43
PKM P14618 1/20 0.43
HPGD P15428 1/20 0.43
HTT P42858 1/20 0.43
ATM Q13315 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13201448 0.88 NPC1 (0.67) NPC1RAB9ASMN1; SMN2GAAMAPK1
SCHEMBL2945606 0.82 RAB9A (0.77) NPC1RAB9ASMN1; SMN2GAARXRA
SCHEMBL2947763 0.81 HDAC6 (0.44) NPC1RAB9ASMN1; SMN2GAAHDAC6
SCHEMBL2387530 0.80 L3MBTL1 (0.51) NPC1RAB9ASMN1; SMN2MAPK1HDAC6
SCHEMBL6631884 0.80 SMN1; SMN2 (0.57) NPC1RAB9ASMN1; SMN2GAAMAPK1
SCHEMBL31003371 0.80 NPC1 (0.56) NPC1RAB9ASMN1; SMN2GAAMAPK1
SCHEMBL2951915 0.79 RARB (0.45) NPC1RAB9ASMN1; SMN2MAPK1HDAC6
SCHEMBL12211224 0.77 LIPG (0.54) NPC1RAB9ASMN1; SMN2LIPGMEN1
SCHEMBL13447882 0.76 HDAC6 (0.53) NPC1RAB9ASMN1; SMN2GAAMAPK1
SCHEMBL12211197 0.75 LIPG (0.68) HDAC6LIPGMEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7754886-B2 N-acylsulfonamide apoptosis promoters ABBOTT LABORATORIES (US) 2010-07-13 US disclosed
US-20090137585-A1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2009-05-28 US disclosed
US-7504512-B2 N-acylsulfonamide apoptosis promoters ABBOTT LABORATORIES (US) 2009-03-17 US disclosed
EP-1318978-B1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBOTT LAB (US) 2006-02-08 EP disclosed
US-20040192681-A1 N-acylsulfonamide apoptosis promoters ABBVIE INC. 2004-09-30 US disclosed
US-6720338-B2 BCL-X1 INHIBITING COMPOSITIONS AND METHODS OF PROMOTING APOPTOSIS IN A MAMMAL ABBOTT LABORATORIES 2004-04-13 US disclosed
EP-1318978-A2 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS Abbott Laboratories (US) 2003-06-18 EP disclosed
US-20020086887-A1 N-Acylsulfonamide apoptosis promoters ABBVIE INC. 2002-07-04 US disclosed
US-20020055631-A1 N-acylsulfonamide apoptosis promoters ABBOTT LABORATORIES 2002-05-09 US disclosed
WO-2002024636-A2 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020086887-A1 N-Acylsulfonamide apoptosis promoters BAX, BCLAF1, BCL2 NPC1 2540/4885RAB9A 4211/4885SMN1; SMN2 1440/4885
US-20020055631-A1 N-acylsulfonamide apoptosis promoters BAX, BCLAF1, BCL2 NPC1 2435/4885RAB9A 3769/4885SMN1; SMN2 1656/4885
US-20040192681-A1 N-acylsulfonamide apoptosis promoters BAX, BCLAF1, BCL2 NPC1 2540/4885RAB9A 4211/4885SMN1; SMN2 1440/4885
US-20090137585-A1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS BAX, BCL2, BCOR NPC1 3122/4885RAB9A 3753/4885SMN1; SMN2 1713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.